Trademarkia Logo

Canada

C$
Trademark Search in Canada
EVELO

View On IC.GC.CA

EVELO
ABANDONED SECTION 36

on 13 Mar 2025

Last Applicant/ Owned by

Evelo Biosciences, Inc.

620 Memorial Drive, Suite 200WCambridge, MA 02139

US

Serial Number

2006914 filed on 8th Jan 2020

Correspondent Address

KATHARINE ZAYACK

(Zayack & Associates Inc.)38 Gifford StreetToronto

ONTARIO

CA

M5A3J1

EVELO

Trademark usage description

pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; pharma Read More

Classification Information

Class [005]
Pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; Pharmaceuticals used to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases; pharmaceuticals used to prevent disease in the nature of allergies and disrupted microbial community associated with allergies; Pharmaceuticals used to prevent disease in the nature of metabolic disorders; pharmaceuticals used to prevent cardiovascular, neuro-degenerative, and neuro-psychiatric diseases; pharmaceuticals used to treat and cure neoplastic conditions, pre-neoplastic conditions and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure allergies and disrupted microbial community associated with allergies in human and animal subjects; pharmaceuticals used to treat and cure metabolic disorders and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects ;pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of neoplastic conditions, pre-neoplastic conditions and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of allergies and disrupted microbial community associated with allergies; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of metabolic disorders and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with the aforementioned conditions; live bacteria, inactivated bacteria, recombinant bacteria and bacterial extracts; biological preparations in the nature of microorganisms to prevent disease in the nature of neoplastic conditions and pre-neoplastic conditions in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of allergies in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of metabolic disorders in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of microorganisms to treat and cure neoplastic conditions and pre-neoplastic conditions in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure inflammation and autoimmune diseases in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure allergies in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure metabolic disorders and cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases in animal or human subjects; biological preparations in the nature of microorganisms to maintain and restore health in animal or human subjects via treatment of inflammation, neuro-inflammation, autoimmune diseases, allergies, metabolic disorders, cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of microorganisms to maintain and restore health in animal or human subjects via treatment of neoplastic conditions and pre-neoplastic conditions; cultures of microorganisms and preparation of microorganisms in the nature of bacterial and bacteriological preparations, all for medical and veterinary purposes, the foregoing for medical purposes; vaccines; therapeutic vaccines; vaccine preparations.

Classification kind code

11

Class [042]
Medical research; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines.

Classification kind code

11

Mark Details

Serial Number

2006914

Mark Type

Trademark

Legal History

Action TakenStatus
Submitted for opposition 6
on 13th Mar 2025		Abandoned - Section 36
Submitted for opposition 14
on 23rd Dec 2024		Default Notice Sent
Submitted for opposition 22
on 5th Jun 2024		Search Recorded
Submitted for opposition 20
on 5th Jun 2024		Examiner's First Report
Submitted for opposition 287
on 14th Apr 2022		Pre-Assessment Letter Sent
Submitted for opposition 15
on 5th Feb 2020		Correspondence Created
Submitted for opposition 31
on 29th Jan 2020		Formalized
Submitted for opposition 1
on 20th Jan 2020		Created
Submitted for opposition 30
on 8th Jan 2020		Filed